Barry Knight is a Chartered Accountant with more than thirty years’ experience as Finance Director, Chief Financial Officer and Chief Operating Officer with companies operating in the Life Sciences sector.
He first worked with Domainex in 2014 as a consultant and later joined the management team as part-time CFO and Company Secretary, returning to that role in 2019 after a brief spell as part-time CFO for Small Pharma, a London-based biotech. Since 2015, Barry has also been part-time CFO and Company Secretary for Edinburgh Molecular Imaging, a biotech company developing a molecular targeted systemic radiotherapy treatment.
After graduating from the University of Bristol with a BSc in Physics, he qualified as a Chartered Accountant with Josolyne Layton Bennett, a predecessor firm of Ernst & Young and then moved into commerce and industry, joining the head office of Cope Allman International plc, holding a number of finance roles and ultimately being appointed Group Chief Accountant in 1985.
In 1989 he made the move into Life Sciences, becoming Finance and Administration Director of KeyMed, one of the UK’s biggest suppliers of medical equipment, seeing it through ten years of significant growth before joining Trigen, a biotechnology start-up in the cardiovascular field, in 2000.
Barry has subsequently worked for two consultancies serving the Life Sciences sector, as Chief Operating Officer for Kinapse Ltd and as Finance Director for AIM-listed Fulcrum Pharma plc.